Interpace Diagnostics Group Inc (NASDAQ:IDXG) rose 6.5% on Tuesday . The company traded as high as $1.04 and last traded at $0.98. Approximately 1,851,700 shares changed hands during mid-day trading, a decline of 9% from the average daily volume of 2,032,684 shares. The stock had previously closed at $0.92.

IDXG has been the subject of a number of research reports. Maxim Group reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Interpace Diagnostics Group in a research note on Tuesday, November 14th. ValuEngine raised Interpace Diagnostics Group from a “strong sell” rating to a “sell” rating in a research note on Monday, September 11th.

The firm has a market capitalization of $24.70, a P/E ratio of 0.32 and a beta of 1.59.

A hedge fund recently bought a new stake in Interpace Diagnostics Group stock. Sabby Management LLC acquired a new stake in Interpace Diagnostics Group Inc (NASDAQ:IDXG) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 529,819 shares of the business services provider’s stock, valued at approximately $476,000. Sabby Management LLC owned approximately 2.39% of Interpace Diagnostics Group at the end of the most recent quarter. Institutional investors and hedge funds own 5.87% of the company’s stock.

WARNING: This piece was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at

About Interpace Diagnostics Group

Interpace Diagnostics Group, Inc, formerly PDI, Inc, is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management.

Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with's FREE daily email newsletter.